Another release of the same info ...
Wednesday February 17, 12:22 pm Eastern Time
Company Press Release
SOURCE: Celsion Corporation
Celsion's Technology May Offer Alternative to Mastectomy
COLUMBIA, Md., Feb. 17 /PRNewswire/ -- Celsion Corporation (OTC Bulletin Board: CELN - news) announced that Massachusetts General Hospital has filed a patent application for a system designed to offer a minimally invasive method for breast cancer prevention. It is believed that Celsion's ''Focused Heat Technology,'' has the ability to target and focus heat exclusively on tumors and diseased areas, without damaging healthy tissue and skin. Pre- clinical studies at Massachusetts General Hospital last year, verified that Celsion's system is capable of selectively heating tumors at temperatures of 46 degrees Celsius with no damage to surrounding healthy tissue. These temperatures, maintained for 8-10 minutes, can kill the entire tumor by eliminating all cancer cells within the tumor and its vicinity. Another pre- clinical evaluation performed in England, also confirmed Celsion system's ability to focus deep heat.
In September 1997, Celsion's focused heat cancer treatment received FDA approval for commercialization as an adjunct to radiation therapy. In 23 worldwide studies, the application of heat in conjunction with radiation therapy doubled the complete response rate of cancerous tumors, compared to radiation alone. Comparable results have been achieved using chemotherapy.
It is expected that Celsion's focused heat technology will be utilized in clinical studies at Massachusetts General Hospital this spring, to ablate breast cancer tumors. Massachusetts General Hospital has also filed a patent application for a breast cancer prevention design using Celsion's technology. ''This could be an improvement in prophylactic breast cancer treatment,'' explained Dr. Gerald Wolf, director of the Center for Imaging and Pharmaceutical Research at Massachusetts General Hospital, and principal investigator of the Celsion clinical trials. ''We look forward to evaluating the system's potential to eliminate the cells that cause cancer. Rather than removing the breasts, we hope to provide a non-surgical alternative for women with a high risk of developing breast cancer,'' stated Dr. Wolf.
Subject to FDA approval, Celsion's breast cancer treatment system is expected to be available by the end of next year. In addition to the breast cancer system, Celsion is also conducting clinical studies towards the FDA approval of its non-surgical treatment for the symptomatic relief of benign prostatic hyperplasia.
For More Information Please Contact:
Patricia Baker
The Big Picture Agency
180 Berkshire Ave.
Southwick, MA 01077
Tel. 413-569-1595 Fax 413-569-6848
SOURCE: Celsion Corporation
biz.yahoo.com
|
